Nonalcoholic fatty liver disease: A negative risk factor for colorectal cancer prognosis

Medicine (United States)

Volumn 94, Issue 5, 2015, Pages e479-

  You, Jie ^a   Huang, Sha ^c   Huang, Gui Qian ^c   Zhu, Gui Qi ^b,c   Ma, Rui Min ^a   Liu, Wen Yue ^b   Shi, Ke Qing ^b,c   Guo, Gui Long ^a   Chen, Yong Ping ^b,c   Braddock, Martin ^d   Zheng, Ming Hua ^b,c  

^a Department of Oncological Surgery ^*  (United Kingdom)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR INVASION; ULTRASOUND; UNIVARIATE ANALYSIS; URIC ACID BLOOD LEVEL; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84922949128     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000479     Document Type: Article

References (46)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. Cancer J Clin. 2014;64:104-117.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490-1502.
3. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
4. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenomacarcinoma sequence. Br J Surg. 2002;89:845-860.
5. Guo P, Huang ZL, Yu P, et al. Trends in cancer mortality in China: an update. Ann Oncol. 2012;23:2755-2762.
6. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22:1958-1972.
7. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645.
8. Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26:863-876.
9. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and metaanalysis. Int J Cancer. 2009;124:2406-2415þ.
10. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PloS One. 2013;8:e53916.
11. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690.
12. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
13. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol. 2014;6:263-273.
14. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-1934.
15. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020-1023.
16. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141-1145.
17. Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829-836.
18. Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25:562-567.
19. Lin XF, Shi KQ, You J, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep. 2014;41:2989-2997.
20. Min YW, Yun HS, Chang WI, et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2012;36:78-83.
21. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023.
22. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabet Res. 2012;2012:145754.
23. Liu D, Li Q, Yang Z, et al. Association of body mass index and smoking on outcome of Chinese patients with colorectal cancer. World J Surg Oncol. 2013;11:271.
24. Parkin E, O'Reilly DA, Sherlock DJ, et al. Excess adiposity and survival in patients with colorectal cancer: a systematic review. Obes Rev. 2014;15:434-451.
25. Wu S, Liu J, Wang X, et al. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies. Cancer Causes Control. 2014;25:1489-1502.
26. Chang Y, Ryu S, Sung E, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009;58:1419-1425.
27. Mills KT, Bellows CF, Hoffman AE, et al. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56:1304-1319.
28. Jeon JY, Jeong DH, Park MG, et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PloS One. 2013;8:e55196.
29. Bella F, Minicozzi P, Giacomin A, et al. Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. J Cancer Res Clin Oncol. 2013;139:1303-1310.
30. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105:1567-1573.
31. Choi WM, Lee JH, Yoon JH, et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr Related Cancer. 2014;21:343-353.
32. Chi F, Wu R, Zeng YC, et al. Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. Mol Biol Rep. 2013;40:3583-3590.
33. Liu R, Hu LL, Sun A, et al. mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes. Arch Med Res. 2014;45:318-324.
34. Kuklinski A, Kamocki Z, Cepowicz D, et al. Relationships between insulin-like growth factor i and selected clinico-morphological parameters in colorectal cancer patients. Pol Przegl Chir. 2011;83:250-257.
35. Arturi F, Succurro E, Procopio C, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011;96:E1640-1644.
36. Fusco A, Miele L, D'Uonnolo A, et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol. 2012;77:531-536.
37. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.
38. Procaccini C, Galgani M, De Rosa V, et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr Pharm Design. 2010;16:1902-1912.
39. Saxena A, Chumanevich A, Fletcher E, et al. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Bioch Biophys Acta. 2012;1822:527-536.
40. An W, Bai Y, Deng SX, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21:126-133.
41. Ye C, Wang J, Tan S, et al. Meta-analysis of adiponectin polymorphisms and colorectal cancer risk. Int J Med Sci. 2013;10:1113-1120.
42. Wang J, Guo XF, Yu SJ, et al. Adiponectin polymorphisms and nonalcoholic fatty liver disease risk: a meta-analysis. J Gastroenterol Hepatol. 2014;29:1396-1405.
43. Ferroni P, Palmirotta R, Spila A, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007;27:483-489.
44. Guadagni F, Roselli M, Martini F, et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009;29:3321-3327.
45. Slomian G, Swietochowska E, Malinowska-Borowska J, et al. Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep. 2014;66:902-907.
46. Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21:87-97.